Codexis (NASDAQ:CDXS) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Codexis (NASDAQ:CDXS) posted its earnings results on Thursday. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.09), Zacks reports. The firm had revenue of $21.46 million during the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. Codexis updated its FY 2025 guidance to EPS.

Codexis Price Performance

NASDAQ CDXS opened at $3.04 on Friday. The firm has a market capitalization of $247.39 million, a PE ratio of -3.49 and a beta of 2.12. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.21 and a quick ratio of 3.15. Codexis has a 12 month low of $2.56 and a 12 month high of $6.08. The company’s 50 day simple moving average is $4.56 and its 200 day simple moving average is $3.95.

Analyst Ratings Changes

CDXS has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price objective on shares of Codexis in a report on Friday, November 22nd. Benchmark reissued a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.